There is a feeling amongst small bio-tech companies that their skills are being overlooked in the initiatives being developed to confront the problem of drug-resistant bacteria. An alliance of 37 such companies across Europe have pledged to accelerate progress in dealing with this threat by bringing together expertise in the design and development of new antibiotics, the identification and implementation of preventative strategies against resistance and in the design of improved diagnostic technologies to facilitate more appropriate antibiotic treatment.
The BEAM Alliance says it will remain at the forefront of antibiotic drug, device and diagnostic discovery and development as a combined technical and scientific force across Europe. It also intends to stimulate research and development activities focused on combating antibiotic resistance and to promote new policies and regulation around the use and development of antimicrobial resistance strategies.
For more information, click here on http://beam-alliance.eu